Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq analysis for transcriptomes of DAC treated myeloid malignant cell lines expressing p53-R282W

ABSTRACT: RNAseq analysis for transcriptomes of DAC treated myeloid malignant cell lines expressing p53-R282W

PROVIDER: PRJNA518120 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8513790_1.fastq.gz	Fastqsanger.gz
	SRR8513790_2.fastq.gz	Fastqsanger.gz
	SRR8513791_1.fastq.gz	Fastqsanger.gz
	SRR8513791_2.fastq.gz	Fastqsanger.gz
	SRR8513792_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNAseq analysis for transcriptomes of DAC treated myeloid malignant cell lines expressing p53-R282W

Project description:To globally evaluate transcriptome treated by decitabine (DAC) in THP-1 and U937 cells expressing p53-R282W, cells were treated with DMSO or DAC. mRNA was isolated and then subject to deep sequencing, using Illumina HiSeq Xten. The sequence reads that passed quality filters were analyzed using htseq. The expressions had been validated using qRT–PCR using SYBR Green assays. Results and conclusions: Global transcriptional change of THP-1 expressing p53-R282W treated with 5 μM DAC was analyzed. Protein interaction network and Enrichment assay was analyzed with the 216 upregulated genes exemplified by ISG15 and IFI27) (Gfold ≥0.4, (RPKM+1 fold change > 1.5), the type I interferon signaling was hit .Similar observations were achieved in U937 cells.

2025-01-10 | GSE125968 | GEO

RNAseq analysis for transcriptomes of ATO+DAC treated THP-1cell lines expressing p53-R282W or p53 wild-type

Project description:To globally evaluate to what extend the p53 mutant transcription activity can be restored by arsenic trioxide (ATO) and decitabine (DAC) co-treatment, p53-null THP-1 cells introduced with p53-R282W or wild-type p53 were treated with ATO (1 μg/ml) and DAC (5 μM). mRNA was isolated and then subject to deep sequencing, using Illumina HiSeq. The sequence reads that passed quality filters were analyzed using Cutadapt.

2024-07-31 | GSE269126 | GEO

Gene expression data of cancer cells overexpressing p53-R282W with or without decitabine (DAC) treatment

Project description:The goals of this study are to compare transcriptome of tumor cells with p53-R282W treated by DAC

2024-04-30 | GSE173643 | GEO

RNAseq analysis for transcriptomes of ATO+DAC treated THP-1cell lines expressing p53-R282W or p53 wild-type

Project description:RNAseq analysis for transcriptomes of ATO+DAC treated THP-1cell lines expressing p53-R282W or p53 wild-type

| PRJNA1120356 | ENA

Gene expression data of cancer cells overexpressing p53-R282W with or without decitabine (DAC) treatment

Project description:Gene expression data of cancer cells overexpressing p53-R282W with or without decitabine (DAC) treatment

| PRJNA726524 | ENA

RNAseq analysis for transcriptomes of ATO treated U937 cell lines expressing 10 type 1 p53 mutants, type-3 p53-R273H, p53 null, or p53 wild-type

Project description:To globally evaluate to what extend type-1 p53 mutant transcription activity can be restored by arsenic trioxide (ATO) (compared to wild-type p53), p53-null U937 cells introduced with 10 frequent type-1 p53, type-3 p53-R273H (negative control), empty vector or wild-type p53 were treated with or without 1 μg/mL ATO. mRNA was isolated and then subject to deep sequencing, using Illumina HiSeq. The sequence reads that passed quality filters were analyzed using Cutadapt. Results and conclusions: The type-1 p53 mutants are the major cellular targets of ATO in the current cell contexts. The expression profiles of well-established p53 targets in cells expressing wild-type p53 highly correlated with the ones in cells expressing ATO-rescued type-1 mutants, but not those in cells expressing ATO-treated R273H. In cells harboring type-1 mutants, the median expression levels of these targets were elevated by ATO to extents comparable to wild-type p53.

2024-08-01 | GSE182565 | GEO

Transcriptome analysis of mutant p53 (p53-V272M, p53-R282W) rescued by arsenic trioxide (ATO)

Project description:Transcriptome analysis of mutant p53 (p53-V272M, p53-R282W) rescued by arsenic trioxide (ATO)

| PRJNA636976 | ENA

Genes activated by 5-aza-dC (DAC) in pancreatic cancer (KPC-Brca1) epithelial cells

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that resists current treatments. To test epigenetic therapy against this cancer we used the DNA demethylating drug 5-aza-2’-deoxycytidine (DAC) in a KrasLSL-G12D; p53LSL-R270H/+; Pdx1-cre; Brca1flex2/flex2 (KPC-Brca1) mouse model of aggressive stroma-rich PDAC. In untreated tumors, we found globally decreased 5-methyl-cytosine (5mC) in malignant epithelial cells and in cancer-associated myofibroblasts (CAFs), and increased amounts of 5-hydroxymethyl-cytosine (5HmC) in CAFs, in progression from pancreatic intraepithelial neoplasia (PanIN) to PDAC. DAC further reduced DNA methylation and slowed PDAC progression, markedly extending survival in an early treatment protocol and significantly though transiently inhibiting tumor growth when initiated later, without adverse side effects. Escaping tumors contained areas of sarcomatoid transformation with disappearance of CAFs. Mixing-allografting experiments and proliferation indices showed that DAC efficacy was due to inhibition of both the malignant epithelial cells and the stromal CAFs. Expression profiling and immunohistochemistry highlighted DAC-induction of STAT1 in the tumors, and DAC plus gamma-interferon produced an additive anti-proliferative effect on PDAC cells. DAC induced strong expression of the testis antigen DAZL in CAFs. These data show that DAC is effective against PDAC in vivo and provide a rationale for future studies combining hypomethylating agents with cytokines and immunotherapy. Treatment of a short-term explant culture of malignant epithelial cells from a KPC-Brca1 mouse pancreatic carcinoma, with 0.5 micromolar 5-aza-dC (decitabine; DAC) for 48 hours. The experiment includes 3 replicate plates untreated and 3 replicates treated.

2013-01-01 | E-GEOD-42365 | biostudies-arrayexpress

dac

Project description:Drosophila melanogaster dac, dachshund, is differentially expressed in 15 experiment(s);

| FBgn0005677 | ExpressionAtlas

dac

Project description:Drosophila melanogaster dac, dachshund, is expressed in 4 baseline experiment(s);

| FBgn0005677 | ExpressionAtlas